Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Retrospective multicenter study of hydromorphone IV-to-oral conversion in cancer patients
jRCT1040220043Recruiting
- Sponsor
- Nakamura Kazuyo
- Start
- Jul 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of hydromorphone in cancer pain, sponsored by Nakamura Kazuyo. Primary endpoint: Conversion ratio from intravenous to oral hydromorphone. Started Jul 2022; status: recruiting.
02
Drugs
hydromorphone
03
Conditions
cancer pain
Beyond the preview
Go deeper on jRCT1040220043.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1040220043.